Scanlon Meghan's Form 4 filing
Boston Scientific Corp (BSX) · filed Jul 27, 2021
- Accession no.
- 0001225208-21-010901
- Filed
- Jul 27, 2021
- Trade date
- Jul 27, 2021
- Filing delay
- Same day
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $623.4K. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Scanlon MeghanCIK 0001801586 | Officer (SVP,Pres,Urology Pelvic Health) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 27, 2021 | Common Stock | MOption exerciseAcquired | +13,850 | $23.41 | +$324,228.5 | 32,992 | Direct | |
| Jul 27, 2021 | Common Stock | SSaleDisposed | −13,850 | $45.01F3 | −$623,388.5 | 19,142 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 27, 2021 | Common Stock | MOption exerciseDisposed | −13,850 | $0.00 | $0 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
Represents the weighted average sale price. These shares were sold in multiple transactions at $45.00 and $45.02. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.